2008
DOI: 10.1001/archderm.144.9.1236
|View full text |Cite
|
Sign up to set email alerts
|

Pimecrolimus: A Novel Treatment for Cetuximab-Induced Papulopustular Eruption

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
5
0

Year Published

2009
2009
2022
2022

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 10 publications
0
5
0
Order By: Relevance
“…There is evidence that the calcineurin inhibitor pimecrolimus is another treatment option for EGFR-treated patients (27). Acne medication can aggravate dry skin and should therefore not be used.…”
Section: Discussionmentioning
confidence: 99%
“…There is evidence that the calcineurin inhibitor pimecrolimus is another treatment option for EGFR-treated patients (27). Acne medication can aggravate dry skin and should therefore not be used.…”
Section: Discussionmentioning
confidence: 99%
“…Epidermal growth factor receptor inhibitors (EGFRIs) are a group of anticancer agents approved for the therapeutic use on a wide array of solid tumors including, but not limited to, colorectal, nonsmall cell lung, and ovarian cancer [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]. EGFRs are commonly expressed in cancer cells, but can also be found in epidermal keratinocytes and sebocytes.…”
Section: Introductionmentioning
confidence: 99%
“…Upon activation, EGFRs initiate a signaling cascade, promoting the uncontrolled cell division and proliferation of cancer cells. Consequently, EGFRIs prevent the signal transduction of such receptors, thereby impeding the growth of solid tumors [1,2,[4][5][6][7][11][12][13][14][15]. EGFRI therapy is known to cause mild to severe skin eruptions in upwards of 90% of patients [14].…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations